Stroke

Crocco, Todd J.; Tadros, Allison; Davis, Stephen M.

doi:10.1002/9781118990810.ch21

Cited by 1 publication

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is estimated that stroke is the second largest cause of death globally, with estimated global lifetime risk of 24.9% from the age of 25 years onward [ 1 ]. Ischemic stroke, the most common stroke type, is associated with high morbidity, mortality, and disability rates [ 2 ] and has a serious impact on the prognosis of patients; for example, patients with dysphagia due to ischemic stroke tend to suffer from pneumonia [ 3 ], and poststroke cognitive impairment significantly decreases the quality of life for patients [ 4 ]. Accumulating clinical evidence has shown that Chinese medicine including herbal medicine, acupuncture, and Tuina (Chinese massage) plays a vital role in the treatment of ischemic stroke [ 5 – 8 ].…”

Section: Introductionmentioning

confidence: 99%

Protocol of the Development of a Core Outcome Set for Ischemic Stroke in Clinical Trials of Chinese Medicine

Xie

Deng

Xiao

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Ischemic stroke (IS) seriously impacts the quality of life of survivors. Chinese medicine (CM) has been developed for more than 2000 years and plays a key role in the treatment of ischemic stroke. Many Chinese medicine clinical trials have been conducted; however, the heterogeneity of outcome measurements and reporting limits implications of the findings in clinical practice and health policy development. Therefore, it is important to develop a core outcome set (COS) that should be used and reported in trials for ischemic stroke treated by Chinese medicine. This protocol describes the process of developing the IS-CM-COS. Methods and Analysis. The development of the COS will involve the following four steps: (1) A list of outcomes reported in the registered and published Chinese medicine trials of ischemic stroke will be extracted by conducting a systematic literature review. (2) An additional outcome list will be collected by semistructured interview to patients with ischemic stroke. (3) A two-round Delphi survey will be performed to prioritize and condense the outcomes. (4) In the consensus meeting, a final recommended COS will be developed. Discussion. The COS could improve the reliability and consistency of outcome reporting. We hope that this IS-CM-COS will be used in the future Chinese medicine trials for the treatment of ischemic stroke and improve research quality. Trial Registration. This study was registered with the Core Outcome Measures in Effectiveness Trials Initiative (http://www.comet-initiative.org/studies/details/1282).

show abstract